169 related articles for article (PubMed ID: 29760872)
1. Giant morphea-form basal cell carcinoma of the umbilicus: Successful debulking with vismodegib.
Orduz Robledo M; Lebas E; Reginster MA; Baghaie M; Groves S; Nikkels AF
Rare Tumors; 2018; 10():2036361318772938. PubMed ID: 29760872
[TBL] [Abstract][Full Text] [Related]
2. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome.
Booms P; Harth M; Sader R; Ghanaati S
Ann Maxillofac Surg; 2015; 5(1):14-9. PubMed ID: 26389028
[TBL] [Abstract][Full Text] [Related]
4. Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face.
Block AM; Alite F; Diaz AZ; Borrowdale RW; Clark JI; Choi M
Case Rep Oncol Med; 2015; 2015():827608. PubMed ID: 26504605
[TBL] [Abstract][Full Text] [Related]
5. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
6. Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.
Su MG; Potts LB; Tsai JH
Am J Ophthalmol Case Rep; 2020 Sep; 19():100755. PubMed ID: 32490287
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
8. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.
Dréno B; Kunstfeld R; Hauschild A; Fosko S; Zloty D; Labeille B; Grob JJ; Puig S; Gilberg F; Bergström D; Page DR; Rogers G; Schadendorf D
Lancet Oncol; 2017 Mar; 18(3):404-412. PubMed ID: 28188086
[TBL] [Abstract][Full Text] [Related]
9. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
Zhu GA; Sundram U; Chang AL
JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
[TBL] [Abstract][Full Text] [Related]
10. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma.
Alcalay J; Tauber G; Fenig E; Hodak E
J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib.
Castillo JM; Knol AC; Nguyen JM; Khammari A; Saint-Jean M; Dreno B
Eur J Dermatol; 2016 Oct; 26(5):452-459. PubMed ID: 27346829
[TBL] [Abstract][Full Text] [Related]
12. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
13. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
14. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
15. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
[TBL] [Abstract][Full Text] [Related]
17. [Locally advanced basal-cell carcinoma: Combined alternative treatments beyond surgery].
Amici JM; Beylot-Barry M
Ann Chir Plast Esthet; 2015 Aug; 60(4):321-5. PubMed ID: 25708732
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma.
González AR; Etchichury D; Gil ME; Del Aguila R
Ophthalmic Plast Reconstr Surg; 2019; 35(1):56-61. PubMed ID: 30444747
[TBL] [Abstract][Full Text] [Related]
20. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
Sofen H; Gross KG; Goldberg LH; Sharata H; Hamilton TK; Egbert B; Lyons B; Hou J; Caro I
J Am Acad Dermatol; 2015 Jul; 73(1):99-105.e1. PubMed ID: 25913533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]